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Mitochondriaarethemainintracellularlocationforfuelgeneration;however,theyarenotjustpowerplantsbutinvolvedinarange
of other intracellular functions including regulation of redox homeostasis and cell fate. Dysfunction of mitochondria will result in
oxidativestresswhichisoneoftheunderlyingcausalfactorsforavarietyofdiseasesincludingneurodegenerativediseases,diabetes,
cardiovascular diseases, and cancer. In this paper, generation of reactive oxygen/nitrogen species (ROS/RNS) in the mitochondria,
redox regulatory roles of certain mitochondrial proteins, and the impact on cell fate will be discussed. The current state of our
understanding in mitochondrial dysfunction in pathological states and how we could target them for therapeutic purpose will also
be brieﬂy reviewed.
1.Introduction
Mitochondria are the main intracellular location for gener-
ating adenosine triphosphate (ATP), the fuel for cell’s met-
abolic needs, and therefore are referred to as the power
plants of the cell. Energy is stored in the form of phosphate
bond and is released when ATP is hydrolyzed to adenosine
diphosphate (ADP) to meet the requirement of a number
of energy demanding cellular processes. ATP is generated
through cellular respiration, including a set of chemical
reactions named as the tricarboxylic acid (TCA) cycle and
oxidative phosphorylation that take place in mitochondria;
therefore, mitochondria play a crucial regulatory role in
cellularmetabolism[1].However,mitochondriaarefarmore
than just power suppliers. They are also involved in many
other cellular functions, including calcium signaling [2],
heme [3] and steroid synthesis [4], regulation of membrane
potential [1], proliferation [5]o ra p o p t o s i s[ 6], and redox
homeostasis maintenance [7], to name just a few. Mitochon-
dria are the major sites for free radical species production,
including both reactive oxygen species (ROS) and reactive
nitrogen species (RNS). On one hand, free radical species
are indispensable for proper cell signaling; on the other
hand, excessive generation of ROS results in cell/tissue injury
and death. In this paper, the underlying mechanisms for
generation of free radical species in the mitochondria and
howsomemitochondrialproteinsactasredoxregulatorswill
be of prime focus. In the past decade, more and more pieces
of evidence are surfacing to point the role of ROS as critical
mediators of the balance between cell proliferation and cell
death [8–10]. Therefore, the involvement of mitochondria
in cell death, especially from the noncanonical view where
mitochondria regulate cell death through manipulating the
redox millieu will also be reviewed. Due to the fundamental
regulatoryroleofmitochondria,disturbancesoftheintegrity
oftheirfunctionswillresultincellulardysfunctionleadingto
various pathological states or even death. Therefore, a good
understanding of the basic mitochondrial biology will help
in therapeutic design for better disease management.
2. Mitochondrial Functions
2.1. Mitochondria Structure and Metabolism
2.1.1. Mitochondria Structure. Mitochondria are essential to
sustain life as around 98% of the oxygen that we breathe2 Biochemistry Research International
in is consumed by mitochondria for energy production. In
order to understand the basic principles of mitochondrial
bioenergetics, it is necessary to have a brief overview of its
structure ﬁrst. Mitochondria, as thought to have evolved
from a bacterial progenitor and having their own mito-
chondrial DNA pool [11], are bounded by two membrane
systems, including an outer and an inner membrane, and the
space in between is referred to as the intermembrane space;
however, the two layers of membranes occasionally come
into contact with each other to form junctional complexes.
The inner mitochondrial membrane, with multiple inward
folding known as cristae which house membrane-bound
mitochondrial enzymes, serves as the major barrier between
mitochondria and cytoplasm since it is largely impermeable,
thereby preventing small molecules and ionic species from
entering the mitochondrial matrix [1].
2.1.2. TCA Cycle and Electron Transport Chain. The tricar-
boxylic acid (TCA) cycle and the electron transport chain
contribute to the key enzymatic components of the mito-
chondria. During the process of breaking down carbon
substrates into acetyl CoA, reducing equivalents (NADH and
FADH) are produced, which are then fed to the electron
transport chain consisting of Complex I (NADH dehydro-
genase), Complex II (succinate dehydrogenase), Complex
III (ubiquinol cytochrome c reductase), and Complex IV
(cytochrome c oxidase). Electrons move from the reducing
equivalents to Complexes I and II, respectively, which are
then passed onto ubisemiquinone for shuttling to Complex
III followed by Complex IV through cytochrome c. In the
meanwhile, an electrochemical proton gradient is generated
when protons are transferred across the inner mitochondrial
membrane into the intermembrane space coupled to the
electron transfer at Complexes I, III, and IV. This is known
as the proton-motive force, generating the mitochondrial
transmembrane potential, which is usually about negative
150–180mV as compared to the cytoplasm. The inﬂux of
the protons through the proton translocating F1F0-ATP
synthase, driven by this force, is coupled to a chemical
reaction that phosphorylates ADP to ATP [12]. An elec-
trogenic transporter, adenine nucleotide translocase (ANT),
then transports ATP out of the mitochondria to places where
energy demanding cellular processes occur [1].
2.2. Mitochondria and Redox Homeostasis Maintenance
2.2.1. Sources of Mitochondrial Reactive Radical Species
Reactive Oxygen Species (ROS). Mitochondria are the major
sources of free radical species production since unpaired
electrons are generated in the process of oxidative phos-
phorylation. Partial reduction of molecular oxygen by the
unpaired electrons leads to the production of superoxide
anions (O2
￿−) which are one of the reactive oxygen species
(ROS) and readily converted to hydrogen peroxide (H2O2)
by magnesium superoxide dismutase (MnSOD) residing in
mitochondria matrix. H2O2 can be converted subsequently
to the highly reactive oxygen species, hydroxyl radical
(
￿OH), through the Fenton reaction [7]. Unlike H2O2,O 2
￿−
does not diﬀuse that readily across the membrane and thus
for O2
￿− produced in the matrix, the activity of MnSOD
is critical to prevent the mitochondrial matrix components
from oxidative damage.
Although, it is well known that ROS can be generated as
byproducts of oxidative phosphorylation, the question as to
the speciﬁc site(s) along the electron transport chain respon-
sible for ROS generation has always been a hotly debated
topic. It is traditionally believed that under physiological
conditions, Complex I is the main site for mitochondrial
ROS production, where O2
￿− is produced on the matrix
side and rapidly dismutated to H2O2 [13, 14]. In addition,
Complex III has also been reported as a site for O2
￿−
production [15, 16]. It is demonstrated that under ischemic
and apoptotic conditions, O2
￿− production is triggered
at Complex III. This may happen through inhibition of
Complex IV as well as over reduction of the electron trans-
port chain in the event of mounting hypoxic stress [17].
In a more recent review [18], the relative contribution of
each complex towards O2
￿− production has been clearly
quantitated with Complexes I (producing O2
￿− to the
matrix) and III (producing O2
￿− to both the matrix and
intermembrane space) having the greatest maximum capac-
ities while Complex II has normally negligible rates.
AnothermajorsourceofROSproductioninthecellisthe
NADPH oxidase (Nox) family proteins, which are enzyme
complexes catalyzing the electron transfer from NADPH to
molecular oxygen, generating O2
￿− and H2O2. The relative
quantitative contribution of mitochondria and NADPH
oxidaseincellularROSproductionisexpectedtovarygreatly
from one cell type to another. In certain cells including the
phagocytic neutrophils as well as nonphagocytic ﬁbroblasts,
vascular smooth muscle cells and endothelial cells, cellular
ROS production is largely contributed by NADPH oxidase
[18–20]. It has been recently reported that one of the
Nox isoforms, Nox4, is expressed in the mitochondria in
the rat renal cortex [21], cardiac myocytes [22, 23], and
in the mitochondria-enriched heavy membrane fractions
of the chronic myeloid leukemia cells that overexpress
the antiapoptotic protein Bcl-2 (CEM/Bcl-2) [24]. Nox4
expression was shown to correlate with dihydroethidium
staining for O2
￿−. In Nox4-transgenic mice cysteine residues
of mitochondrial proteins were also more oxidized [23].
However, there are no direct and speciﬁc measurements of
Nox4 activity in the mitochondria up to date. Meanwhile,
the cytoplasmic Nox4 may be involved in the activation of
PKCε,m i t o K ATP and modulation of thioredoxin 2 activity
resulting in redox-sensitive upregulation of mitochondrial
ROS production through the electron transport chain [25].
Apart from the electron transport chain and the NOX
family, several other sites in the mitochondria have also
been reported to generate O2
￿−, including pyruvate dehy-
drogenase, α-ketaglutarate dehydrogenase [26], glycerol-3-
phosphate dehydrogenase, and fatty acid β-oxidation [18].
Recently, new ﬁndings that supported the concept of
mitochondrial O2
￿− ﬂashes have gained much interest and
revealed several previously unknown aspects of mitochon-
drialdynamics.TransientquantalO2
￿− ﬂasheswereobserved
in excitable cells such as muscle cells and neurons in vivoBiochemistry Research International 3
and they are associated with mitochondrial permeability
transition pore (mPTP) opening, which presents a new facet
in physiological ROS production [27–29].
Reactive Nitrogen Species (RNS). Apart from ROS gener-
ation, there is evidence to suggest the expression of a
mitochondrial speciﬁc nitric oxide synthase (NOS) leading
to
￿NO production. It was ﬁrst described in 1997 by Ghaf-
ourifar and Richter that
￿NO was generated from isolated
mitochondria when they were loaded with calcium and
mitochondrial potential dropped in some of the treated
mitochondria [30]. Another group provided more direct
evidence by showing images of calcium regulated
￿NO pro-
duction within the mitochondria of permeabilized cells,
through the use of the
￿NO-sensitive chromophore, DAF-2
[31].
The impact of
￿NO generation on mitochondrial func-
tions remains controversial, largely depending on the
amount of
￿NO that is produced as well as the condi-
tions under which it is produced. It has been shown that
mitochondrial respiration can be partially inhibited with
even the modest levels of
￿NO causing an increase in
mitochondrial ROS production. This also results in mito-
chondrial depolarization resulting in a decrease in mito-
chondrial calcium uptake [32]. The inhibitory eﬀect of
￿NO
on mitochondrial respiration has been shown to mainly
result from inactivation of cytochrome c oxidase (Complex
IV) [33–40], which is the rate-limiting step of the electron
transport chain. Being a double-edged sword,
￿NO was
demonstrated to play a role in mitochondrial biogenesis as
well, which gets stimulated by
￿NO generation through a
cGMP-dependent upregulation of PGC1α expression, which
in turn increases the expression of mtTFA and NRF-1 result-
ing in an increased mitochondria biosynthesis observed in
adipocytes and hepatocytes [41]. Another group also showed
a physiological role for
￿NO generation in mitochondrial
mass regulation where endothelial-
￿NO-synthase- (eNOS-)
deﬁcientmiceshoweddeﬁcienciesinmitochondrialenzymes
[42]. In addition, protective eﬀect of
￿NO on mitochondria
and cells is also observed against ischemia/reperfusion (I/R)
injury (late preconditioning). It has been suggested that
partial temporary inhibition of Complex I might be involved
in this eﬀect via inhibition of ROS burst in reperfusion.
Furthermore, treatment with diet inorganic nitrates or
administration of nitrites or S-nitroso-2-mercaptopropionyl
glycine (SNO-MPG) confers cardioprotection against the
injury via temporary S-nitrosylation of various cellular
protein targets [43].
On the contrary, under some pathological stimuli, ex-
cessive production of
￿NO could result in severe tissue
damage. Several groups have suggested that in the face of
a high concentration of
￿NO with a relatively low oxygen
concentration, respiration can be inhibited resulting in an
increased O2
￿− production, which will react with the freely
membrane diﬀusible
￿NO to form a much more reactive
radical species, peroxynitrite (ONOO−). Peroxynitrite can
also be formed through an alternative route via the reaction
ofnitroxylanion(NO−)andmolecularoxygen[44].Nitroxyl
anion can be derived from
￿NO through one electron
reduction by the electron donors including cytochrome c
[45] or ubiquinol [46]. Due to its ability to diﬀu s ea c r o s st h e
mitochondrial membranes, ONOO− can result in oxidative
damageofcriticalcomponentsthroughoutthemitochondria
via oxidation, nitration, and/or nitrosation. For example,
thiols present in Complex I can be oxidized leading to the
formation of an S-nitrosothiol derivative and inactivation of
the complex [47–49]. Complexes II and V were also shown
to be inactivated by ONOO− [34, 44, 48–53]. MnSOD, the
matrix antioxidant enzyme, is also a target for nitration
leading to a decrease in its enzymatic activity [54]. Adenine
nucleotide translocase (ANT) [55], creatine kinase [56],
nicotinamide nucleotide transhydrogenase [57], aconitase
[58], and components of the pyridine nucleotide-dependent
calcium release pathway [59] are all targets of ONOO−.
Therefore, ONOO− has profound eﬀects on mitochondrial
metabolism, calcium homeostasis, and the mitochondrial
permeability transition pore [42]. In addition, ONOO− has
been shown to uncouple eNOS, leading to a switch from
￿NO to O2
￿− production and an increase in mitochondrial
R O Sl e v e l sa sw e l l[ 42, 60].
Of particular note, carbon monoxide (CO), an endoge-
neous gas produced by heme oxygenase (HO) that catalyzes
heme degradation, is able to induce the production of ROS
andRNSas wellduetoits high aﬃnity forreduced transition
metalssuchasFe2+.For example,it binds toComplex IVand
slows the terminal transfer rate of electrons to molecular O2
leading to enhanced O2
￿− production [61].
2.2.2.MitochondriainRedoxRegulation. Sincemitochondria
are major sources for ROS production, it is not surprising
that they are well equipped with antioxidant defenses,
including alargepool ofglutathione,glutathione peroxidase,
glutathionereductase,MnSOD,catalase,andthethioredoxin
system [1, 62].
Although excessive levels of ROS will lead to protein
oxidation and lipid peroxidation causing damage to mito-
chondrial membrane, proteins, and DNA, especially when
the mitochondrial DNA is not protected with associated
histones, lower levels of ROS have been demonstrated to be
essential signaling molecules [7, 63, 64]. A new concept is
now emerging that mitochondrial ROS production is likely
to be highly regulated as a part of physiological mitochon-
drial functions and the underlying molecular mechanisms
are being gradually uncovered [7]. In this paper, a few
mitochondrial proteins that act as redox regulators will be
discussed as examples, including the antiapoptotic protein
Bcl-2, cytochrome c oxidase (COX), and the small GTPase
Rac1.
Bcl-2 and Its Eﬀect on Mitochondrial ROS Generation. Bcl-
2, one of the antiapoptotic members of the Bcl-2 family
proteins residing on the outer mitochondrial membrane
[65], is best known for its ability to inhibit apoptotic exe-
cution, that is, to form homo- and heterodimers to prevent
the oligomerization of proapoptotic Bcl-2 family members,
thus antagonizing the induction of mitochondrial outer
membranepermeabilization(MOMP)[66].However,recent
evidence points to a new facet of Bcl-2 biology in redox4 Biochemistry Research International
regulation. The involvement of Bcl-2 in redox regulation
was ﬁrst demonstrated by Hockenbery et al. that Bcl-2 over-
expression protected against ROS-induced apoptosis [67].
Soon after other studies also revealed the protective capacity
of Bcl-2 against various ROS triggers [68–73]. However, Bcl-
2itselfwaslaterfoundouttopossessnointrinsic antioxidant
ability [74] implying that rather its overexpression indirectly
induces an enhancement in antioxidant capacity of the cells
when they undergo overt oxidative stress [66, 75] and this
is supported by the ﬁndings that Bcl-2-mediated protection
is associated with upregulation of the cellular enzymatic and
nonenzymaticantioxidantdefensemachineriesincludingthe
glutathione system, catalase, and NAD(P)H [74, 76–79].
More recently, a clearer picture of Bcl-2 with respect to its
ability to regulate redox status is emerging, and a prooxidant
role of Bcl-2 is established under normal physiological states
[77, 80–84]. Based on this prooxidant property of Bcl-2,
it implies that the enhanced antioxidant capacity that was
observed with Bcl-2 overexpression could be an adaptive
response to the chronic but mild oxidative intracellular
milieu [70, 74, 76, 79, 83] and this serves as a ﬁrst-line
defense in the event of acute oxidative insults maintaining
the ROS levels within a threshold optimal for cell survival
[66, 75, 81, 85].
The underlying mechanisms on how Bcl-2 exerts its
prooxidant activity, however, have not been fully elucidated.
It was ﬁrst hypothesized that the prooxidant milieu in
Bcl-2 overexpressing mitochondria resulted from an altered
dynamics of the oxidative phosphorylation. An increase
in mitochondrial size and associated matrix content was
observed with Bcl-2 overexpression and this indicated an
increase in the number of electron donors and a subsequent
increase in the chance of electrons leaking out of the electron
transport chain to form O2
￿− [77, 86]. However, the exact
mechanism linking Bcl-2 expression levels to mitochondrial
size and matrix content was not addressed in the above-
mentioned studies. More recently, our group has established
the inherent ability of Bcl-2 to generate intramitochondrial
O2
￿− by engaging mitochondrial respiration in tumor cells.
An increased mitochondrial oxygen consumption rate and
cytochrome c oxidase (COX or Complex IV) activity was
observed in Bcl-2 overexpressing cells [81, 85, 87]. It is
plausible that the increased mitochondrial respiration rate
results in an increased electron ﬂux across the electron
transport chain and an increased probability of leakage of
electrons onto molecular oxygen thus leading to an increase
in the by-production of O2
￿−. Indeed, either silencing of
Bcl-2 with siRNA or functional inhibition of Bcl-2 with
the BH3 mimetic, HA14-1, in those cells, reversed both
the oxygen consumption rate as well as the O2
￿− levels
[81]. This is further supported by the observation that
mitochondrial respiratory rate and O2
￿− levels correlated
with Bcl-2 expression levels across diﬀerent tumor cell lines
with various endogeneous Bcl-2 levels [85]. Of note, Bcl-
2 overexpression promoted the mitochondrial localization
of COX Va and Vb, which are nuclear encoded subunits
of Complex IV, which could explain for the signiﬁcantly
increased Complex IV activity in these cells [85]; it has
been previously shown that mitochondrial level of COX
Vb correlated with the COX holoenzyme activity [88]. Of
particular note, the increased O2
￿− release as induced by
Bcl-2 overexpression might seem contradictory to what we
mentioned in the earlier section that inhibition of ETC by
￿NOalsoresultsinO2
￿− release.However,theformeroccurs
as a result of increased electron ﬂux across the electron
transport chain and an increased probability of leakage
of electrons onto molecular oxygen while the latter is the
result of inhibition of reduction step along the ETC leading
to promotion of the reaction of oxygen with accumulated
reductants [89].
More recently, our group has identiﬁed another func-
tional player in Bcl-2-mediated prooxidant state, the small
GTPase Rac1 [24]. Rac1 is known to be involved in the
assembly and activation of NADPH oxidase complex leading
to O2
￿− production. It was ﬁrst discovered that introduction
of the dominant negative mutant Rac1N17 neutralized the
prooxidant activity of Bcl-2 [82]. Later on, a physical in-
teraction was observed between these two proteins in the
outer mitochondrial membrane of tumor cells which could
be blocked with the BH3 mimetics and Bcl-2 BH3 domain
peptides. The intramitochondrial O2
￿− production in Bcl-
2 overexpressing cells was also reversed by BH3 peptides,
which can also be achieved with silencing or functional
inhibition of Rac1 [24].
These data provide evidence for the existence of func-
tional complexes within the mitochondria involving Bcl-2,
buttheprecisemechanismofinteractionandhowdisruption
of these interaction(s) could impact cell fate remains to
be elucidated. Of course, apart from the above-mentioned
proteins, there are many others that act as mitochondrial
redox regulators including the master transcription factor
for cellular antioxidant defense machinery, the transcription
factor NF-E2-related factor 2 (Nrf2), which gets activated
under cellular oxidative stress conditions such as GSH
depletion,
￿NO, and nitrosative stress [90–92]. Interestingly,
a recent paper provided the ﬁrst evidence that activation of
Nrf2 can upregulate Bcl-2 as well [93].
2.3. Mitochondria and Cell Fate Regulation. Since mito-
chondria are fundamental energy generators, severe damage
to mitochondria will inevitably cause disorders in cellular
functions. Once ionic gradients and intracellular osmolarity
cannot be maintained, cells will swell and die through a
death process known as necrosis [94]. However, for some
immortalized cells, they survive reasonably well on ATP gen-
erated from glycolysis even when mitochondrial respiration
iscompletelyinhibited[1,95,96].Apartfromdyingpassively
when the ATP supply fails, cells can also actively undergo
a “suicide” program through the mitochondria-mediated
apoptotic pathway upon compromise in the mitochondrial
outer and/or inner membrane permeability [97]. Further-
more, there is another form of cell death named autophagy,
which degrades cellular organelles and proteins promoting
either survival or death depending on the stress conditions.
Various studies have indicated the involvement of ROS and
mitochondria in autophagic regulation [98, 99]; however,
due to space constraints, it is not covered in this review.Biochemistry Research International 5
2.3.1.Apoptosis. Forthepasttwodecadeorso,mitochondria
have been extensively studied for its essential role in deﬁning
the balance between cell life and death. It was ﬁrst demon-
strated in 1994, that cytochrome c, once it is released from
the intermembrane space of the mitochondria, can initiate
an enzyme cascade of cellular self-destruction. Other death
ampliﬁcation factors, such as the inhibitors of apoptosis
(the IAP family which prevent accidental caspase activation
presumably), smac or diablo (which inhibits IAPs to permit
the apoptotic cascade to proceed), procaspase-9, and AIF
(the ﬂavoprotein apoptosis inducing factor) are also released
to participate in the death execution pathway [97].
2.3.2. Redox Status in Cell Fate Decision. Although over-
whelming amount of ROS are deﬁnitely detrimental to the
cells, emerging evidence has demonstrated that when they
are present in nonlethal concentrations, they can function
as proliferative and/or survival signals [8]. A mild increase
in the O2
￿− has been shown to confer survival advantage
to the tumor cells under apoptotic triggers [8, 10, 100–
103]. Furthermore, it has been demonstrated by our group
that cell fate is tightly regulated as a function of the
ratio of O2
￿− and H2O2. A tilt in the balance of the
two reactive oxygen species towards O2
￿− leads to survival
signaling, while the reverse sensitizes cells to apoptotic
triggers [8–10]. Corroborating the survival advantage of a
mild prooxidant status, the antiapoptotic activity of Bcl-
2 can be contributed to its noncanonical ability to induce
intramitochondrial O2
￿− production. Indeed, Bcl-2 BH3
peptides, which reversed the prooxidant state of Bcl-2-
overexpressing tumor cells, sensitized those cells to drug-
induced apoptosis. Similarly, silencing or pharmacological
inhibition of Rac1 also compromised Bcl-2-induced increase
in intramitochondrial O2
￿− levels leading to sensitization of
those tumor cells to apoptotic triggers [24].
3. Mitochondrial Dysfunction in Pathology and
Therapeutic Targeting
Mitochondria, as one of the major ROS producers within
the cell, have been rendered susceptible to oxidative damage
when the antioxidant defense machinery fails to meet their
ROS scavenging tasks; therefore, they are implicated in the
pathology of various diseases including neurodegenerative
diseases, diabetes, cardiovascular diseases, and cancer [104–
114].
3.1. Neurodegenerative Diseases. ROS-mediated mitochon-
drial dysfunctions and apoptosis have been demonstrated as
causal factors in the pathology of several neurodegenerative
diseases including Parkinson’s disease (PD), Alzheimer’s dis-
ease (AD), and Amyotrophic lateral sclerosis (ALS). Oxida-
tive damage, as indicated by malondialdehyde (MDA) and
4-hydroxynonenal (4-HNE), have been identiﬁed in patients
diagnosed with PD (substantia nigra), AD (hippocampus
and cortex) as well as ALS (spinal ﬂuid) [115–118]. The
levels of Iron are also found to be elevated in the substantia
nigra of patients with PD, which could serve as a catalyst for
the Fenton’s reaction in producing hydroxyl radicals [119–
121], whereas the activities of antioxidant defense enzymes
such as glutathione peroxidase (GPx) and reductase (GR),
superoxide dismutase (SOD) and catalase (CAT) are reduced
in the aﬀected brain regions of patients with AD [117, 122,
123]. Similarly, patients with PD demonstrate diminished
levels of GSH in the dopaminergic neurons of substantia
nigra [118, 119, 124].
Transgenic animals that develop neurodegenerative dis-
eases have been utilized as models to clarify the roles of
oxidative stress in the pathogenesis of these diseases. Trans-
genic mice that harbor an ALS-linked mutant CuZnSOD
gene show progressive accumulation of 8-OHdG, one of the
best markers for oxidative DNA damage, in ventral horn
neurons. The immunoreactivity for this marker indicates
the existence of oxidative damage to mitochondrial DNA
in spinal motoneurons starting from very early stage of
the disease, and probably contributing to the subsequent
motoneuron death [125]. In another model of GPx deﬁ-
cient mice, administration of N-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP) led to enhanced toxicity to
dopaminergic neurons indicating the involvement of ROS in
the early pathogenesis of PD [126]. Triple-transgenic mice
that mimic AD progression in humans also demonstrate
reduced levels of GSH and vitamin E as well as increased
extent of lipid peroxidation during the stage of Amyloid β
(Aβ) oligomerization before the onset of Aβ plaques and
neuroﬁbrillary tangles [127].
Since oxidative stress resulting from depletion of the cel-
lular antioxidant glutathione occured during the early stages
of neurodegeneration, a lot of eﬀort has been dedicated to
study the eﬀects of antioxidants in combating oxidative
stress and preserving the integrity of mitochondria for the
treatment of neurodegenerative diseases. Several examples
of antioxidants that have been demonstrated to attenuate
disease progression will be discussed below.
Curcumin. Curcumin is a polyphenol that belongs to the
ginger family (Zingiberaceae). Curcumin treatment of do-
paminergic neuronal cells and mice restores GSH pools,
which protects against oxidative stress and preserves mito-
chondrial complex I activity, thereby suggesting its ther-
apeutic beneﬁts in the treatment of PD [128]. Protective
eﬀects of curcumin have also been shown against MPP (+)-
induced cytotoxicity and apoptosis by upregulation of Bcl-2
expression and restoring mitochondrial membrane potential
[129]. In addition, tetrahydrocurcumin (THC), a metabolite
of curcumin, has been shown to protect against Aβ-induced
ROS burst, preserve mitochondrial membrane potential,
and prevent caspase activation in rat primary hippocampal
cultures [130].
Apart from oxidative stress, nitrosative stress, largely me-
diated by reactive nitrogen species (RNS) such as OONO−,
is also crucial in PD development by inducing mitochon-
drial dysfunction through inhibition of brain mitochondrial
complex I activity, decrease of mitochondrial membrane
potential, and compromise of mitochondrial integrity. The
glutamoyl diester bioconjugate of curcumin has been shown6 Biochemistry Research International
to restore Complex I activity and protect against protein
nitration [131].
Epigallocatechin-3-Gallate (EGCG). EGCG is the most abu-
ndant polyphenol found in green tea. Apart from its iron-
chelating property, the antioxidant capacity of EGCG has
been demonstrated at the level of mitochondria where it not
only enhances the activities of both TCA cycle enzymes and
ETC complexes but also upregulates the antioxidant system
in aged brain [132]. EGCG has also been shown to increase
the activity of SOD and catalase in mice striatum [133]. The
molecular mechanism underlying the upregulation of the
antioxidant defense machinery is due to the ability of EGCG
toinducetheactivationofNrf2,amastertranscriptionfactor
for antioxidant and phase II detoxifying enzymes [134].
Although these molecules demonstrate protective eﬀects
in animal models of the neurodegenerative diseases, their
beneﬁcial eﬀects in humans have not been clearly demon-
strated in clinical trials, conceivably due to the diﬃculties in
penetrating the blood-brain barrier; therefore a lot of eﬀort
is currently being spent in developing better delivery systems
for speciﬁc targeting, especially to mitochondria, where their
pharmacological activity is mostly required to increase the
therapeutic eﬃcacy [135–138].
3.2. Diabetes, Diabetic Complications, and Cardiovascular
Diseases. Despite the fact that diabetes mellitus (DM) is
a heterogeneous, multifactorial and chronic disease, it can
be stated without doubt that DM is linked to acute and
continuous overproduction of ROS and characterized by
mitochondrial impairment. DM is also marked with chronic
inﬂammation that further weakens intracellular antioxi-
dant defense. Reduced levels of antioxidants such as GSH,
vitamins C and E are observed in diabetic patients [139,
140]. Dysfunction of mitochondrial complex I and subse-
quent increase in ROS production together with decreases
in antioxidant levels and membrane potential have been
reportedindiabeticpatients[141].Riskfactorssuchasaging,
obesity, and unhealthy diet contribute to an oxidative envi-
ronment which impairs insulin signaling and mitochondrial
function leading to diabetes development, and the resulting
hyperglycemia in turn contributes to the maintenance and
progression of the overall oxidative stress through mecha-
nisms such as glycation of antioxidant enzymes [111]a n d
overproduction of O2
− by the mitochondrial ETC, which in
turn activate a variety of proinﬂammatory signals [111, 142–
144].
Malfunctioning of mitochondrial oxidative phosphory-
lation has been considered as one of the main culprits in
the development of diabetic complications as well, such as
renal dysfunction [145]. In addition, it has been reported
that the activities and expression of antioxidant enzymes
are decreased in diabetic microvascular disease [146, 147]
and a speciﬁc polymorphic MnSOD gene is correlated with
diabetic nephropathy development [148]. Protective eﬀects
of catalase overexpression have also been demonstrated in
the experimental models of type 2 diabetic nephropathy,
thereby implicating H2O2 [149]. Majority of the type
2 diabetic patients with insulin resistance also exhibit a
signiﬁcantly higher risk of developing cardiovascular disease
(CVD) [150]. Human atherosclerotic samples show higher
extent of mitochondrial DNA damage, which correlates with
greater ROS production. In apoE-null mice, mitochondrial
damage has been shown to precede the development of
atherosclerosis. In the same model, heterozygous deﬁciency
of MnSOD also increases vascular mitochondrial dysfunc-
tion [151].
Since oxidative stress has been considered as one of the
main contributing factors for the onset and progression of
diabetes,diabeticcomplications,andCVD,theneedtoeradi-
cateROSespeciallyfrommitochondriaisofgreattherapeutic
importance [152]. Although classical antioxidants such as
vitamins C and E do not show signiﬁcant improvement
in disease conditions [153], recent reports show that a
subgroup of type 2 diabetic patients with haptoglobin (Hp)
2-2 genotype can beneﬁt from vitamin E supplementation
suggesting that tailored treatment regimens for diﬀerent
subgroups of patients could be more favorable [154, 155].
MitoQ is an antioxidant that is selectively targeted to and
accumulates in mitochondria due to its covalent attachment
to the lipophilic triphenylphosphonium cation [156]. MitoQ
administration to Ins2(+/) (AkitaJ) mice improves the tubu-
lar and glomerular function and reduces urinary albumin
levels and interstitial ﬁbrosis implicating their therapeutic
beneﬁts in treating diabetic nephropathy [157].
3.3. Cancer
3.3.1. Prooxidant Theory of Carcinogenesis. We have dis-
cussed in the previous Section 2.3.2 how redox status can
aﬀectcellfatedecisionandhowsomemitochondrialproteins
can act as redox mediators. Over the past decade, our
group has been working on the underlying mechanisms and
translational relevance of redox signaling in the context of
carcinogenesis. We have established that cell fate is tightly
regulatedasafunctionoftheratioofO2
￿− andH2O2.Atiltin
the balance of the two reactive oxygen species towards O2
￿−
leads to survival signaling while the reverse sensitizes cells to
apoptotic triggers [8–10].
3.3.2. Mitochondria as Therapeutic Targets in Cancer. Since
mitochondria are key regulators for energy metabolism, ROS
production and cell fate [158], targeting mitochondria to
elicit cell death would therefore be a good strategy in cancer
therapeutics especially in those cancer cells where upstream
apoptotic signaling is malfunctional [159]. In addition, the
bioenergeticdiﬀerencesbetweennontransformedandcancer
cells confer the selectivity and speciﬁcity in targeting small
molecule agents to the mitochondria of desired cancer cells.
For example, lipophilic cations preferentially accumulate
in the mitochondrial matrix of cancer cells due to their
increased mitochondrial membrane potential resulting from
increased glycolytic rates as compared to their normal
counterparts [160, 161]. In addition, the addiction of cancer
cells to glycolysis for ATP supply, described as the Warburg
eﬀect, also renders them more susceptible to apoptotic
induction when their cellular bioenergetic pathways are
intervened [161].Biochemistry Research International 7
Direct Targeting of Mitochondrial ETC. Since mitochondrial
ETC is essential in energy production and ROS generation,
there are a plethora of agents that target ETC directly for
cancer therapeutics [106]. Rotenone is a naturally derived
hydrophobic pesticide, which binds and inactivates mito-
chondrial Complex I irreversibly leading to a blockage of
oxidative phosphorylation and an increase in ROS gen-
eration [162, 163] and ﬁnally apoptotic induction [164–
167]. Therapeutic beneﬁts of Rotenone have been demon-
strated in human breast cancer cells [168], neuroblastomas
[169], promyelocytic leukemias [170], and human B-cell
lymphomas [167]. Tamoxifen and estradiol have also been
reported to act on the ﬂavin mononucleotide site of complex
I leading to mitochondrial failure independent of estrogen
receptors [171], and particularly in MCF-7 breast cancer
cells tamoxifen is able to induce an increase in ROS levels,
a decrease in mitochondrial membrane potential and release
ofcytochromec[172].3-nitropropionicacidisatoxinfound
in fungi and plants that can bind covalently to complex II
[173–175] and its toxicity to tumor cells is linked to cellular
energy depletion and oxidative stress due to the generation
of O2
−,H 2O2,a n dO O N O − [176, 177]. In addition, an
analog of vitamin E, α-tocopheryl succinate (α-TOS) is able
to interfere with the ubiquinone binding site on Complex
II [178] leading to cell cycle arrest and apoptosis in a
host of established cancer cell lines of diﬀerent origin as
well as in in vivo experimental animal models [179–185].
Although α-TOS has been shown to be largely nontoxic
to normal tissues [183], its eﬃciency has not yet been
tested in human cancer patients due to the diﬃculties in
administration [186]. Antimycin A is a secondary metabolite
produced by Streptomyces kitazawensis [187] which binds to
the Qi site of Complex III [188, 189] leading to collapse of
the proton gradient [188], ROS production, and apoptosis
[190]. Fenretinide is a synthetic analog of retinoic acid which
is able to downregulate Complex IV subunit III mRNA
levels leading to a decrease in Complex IV activity [191].
FenretinideinducesapoptosisthroughelevatedROSproduc-
tion, cytochrome c release, and induction of mitochondrial
permeability transition [192, 193], which could be prevented
by the addition of antioxidants [194, 195]. It is likely that
fenretinide inhibits at least one of the complexes along the
ETC, although the exact prooxidant mechanisms are yet
to be elucidated [194, 196]. In vivo therapeutic beneﬁts
of fenretinide have been demonstrated in both carcinogen-
induced or xenograft animal models [197].
Direct targeting of mitochondrial ETC increases ROS
production from the mitochondria of cancer cells which
results in increased susceptibility of those glycolytic addicted
cells to apoptotic induction. However, the critical points
to be taken into consideration when using mitochondrial
respiration “poisons” are their in vivo toxicity and ther-
apeutic indexes. Almost half of the studies as discussed
above failed to actually demonstrate nontoxicity of the
agents to nontransformed cells in vivo except for α-TOS and
fenretinide.
Direct Targeting of Bcl-2 Family Proteins. Apart from tar-
geting the mitochondrial ETC, there is another group
of proteins that are of particular interest due to their
regulatory roles in apoptosis, which is the Bcl-2 family.
We have discussed in Sections 2.2.2 and 2.3.2 that the
ratio between the pro- and antiapoptotic members of Bcl-
2 family is critical in cell fate decision. In addition, Bcl-2, an
antiapoptotic member of the family and a resident protein
o fm i t o c h o n d r i a ,i sa b l et om o d u l a t er e d o xs t a t u sw h i c h
could be utilized in cancer therapeutics as well. Promising
therapeutic strategies that aim at overcoming the problem
of Bcl-2 overexpression (which happens in a number of
cancers) including Bcl-2 antisense and BH3 mimetics have
been recently reviewed by our group [66]. Furthermore,
treatment of membrane active segments of the proapoptotic
member Bax can also induce apoptosis in tumor cells [198].
Indirect Targeting of Mitochondrial Apoptotic Pathway. There
are another group of drugs that do not target mitochondria
directly but rather modulate mitochondrial proteins and/or
induce ROS production leading to induction of intrinsic
mitochondrial apoptotic pathway in cancer cells. These
include clinically used chemotherapies such as irinotecan,
topotecan [199], etoposide [200], vinblastine [201], and
arsenic trioxide [202], which induce mitochondrial apop-
totic pathway as well as those currently undergoing clinical
evaluation such as betulinic acid [203], curcumin [204],
camptothecin derivatives [199], and triapine [205], where
betulinic acid and triapine-induced apoptosis has been
attributed to ROS production.
4. Concluding Remarks
Mitochondria are essential regulators of cellular energy me-
tabolism, redox homeostasis, and cell fate decision, and their
dysfunction inevitably leads to various pathological states
including neurodegenerative diseases, diabetes, cardiovascu-
lar diseases, and cancer as brieﬂy discussed in this review.
Oxidative stress is the underlying causal factor in majority
if not all of the diseases listed above; therefore, therapeutic
strategies that aim at manipulating the redox metabolism
represent promising options which have been and will still
be at the center stage of targeted drug development.
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